The FDA approved encorafenib, cetuximab, and mFOLFOX6 for mCRC with BRAF V600E mutation, based on the BREAKWATER trial results. The trial showed a 61% ORR for the combination therapy, compared to 40% ...

Colorectal cancer (CRC), a type of cancer that affects the large intestine and rectum, is one of the leading causes of cancer-related deaths worldwide. The mutational landscape of CRC is ...

Traditional approval was supported by BREAKWATER, a randomized, open-label phase 3 study in first-line BRAF V600E–mutant metastatic CRC comparing encorafenib/cetuximab plus chemotherapy against ...

Traditional FDA approval covers encorafenib plus cetuximab with fluorouracil-based chemotherapy for adult metastatic CRC with BRAF V600E mutations confirmed by an FDA-authorized test. BREAKWATER ...

A review article led by researchers from the B·ARGO group at the Germans Trias i Pujol Research Institute (IGTP) and from the Medical Oncology Department of the Catalan Institute of Oncology (ICO) in ...

Using AI, we identified publications that likely reported a testing or mutation rate, filtered publications for cancer type, and identified sentences that likely reported rates. Rates and covariates ...

CHICAGO -- First-line treatment with encorafenib (Braftovi) and cetuximab (Erbitux) plus chemotherapy significantly improved survival outcomes compared with standard of care in patients with BRAF ...

SAN FRANCISCO -- First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF ...

Researchers from Japan report that they have characterized gene mutations in colorectal cancer (CRC) tumors with high tumor mutation burden that lack mutations in the major oncogenes. Their findings ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline progression-free (PFS) survival results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, ...